Literature DB >> 21784052

miR-10a overexpression is associated with NPM1 mutations and MDM4 downregulation in intermediate-risk acute myeloid leukemia.

Dmitriy Ovcharenko1, Friedrich Stölzel, David Poitz, Fernando Fierro, Markus Schaich, Andreas Neubauer, Kevin Kelnar, Timothy Davison, Carsten Müller-Tidow, Christian Thiede, Martin Bornhäuser, Gerhard Ehninger, David Brown, Thomas Illmer.   

Abstract

OBJECTIVE: The study investigated differential microRNA (miRNA) expression patterns in acute myeloid leukemia (AML) patients with intermediate-risk (IR) characteristics. After characterization and validation of miR-10a, which was specifically upregulated in nucleophosmin 1 (NPM1) mutant AML samples, functional consequences of miR-10a overexpression were further delineated in vitro.
MATERIALS AND METHODS: Microarray analysis of miRNAs in bone marrow samples from AML (IR) patients with NPM1 mutations and healthy donors was performed to detect differential expression patterns. After validation of miRNA expression specific for NPM1 mutation in AML patients by quantitative reverse transcription polymerase chain reaction, a functional target gene search was conducted using complementary DNA microarray data from samples transfected with miR-10a. Potential target gene validation was done using transient transfection of K562 cells followed by Western blotting and luciferase reporter assay.
RESULTS: In comparison with wild-type samples, NPM1 mutant AML samples were shown to markedly overexpress miR-10a. Subsequent in vitro miR-10a overexpression induced differential gene expression as determined by microarray analysis. Here the murine double minute 4 (MDM4) gene turned out as a candidate gene for miR-10a. Validation of MDM4 in leukemic cells revealed a robust negative relationship between miR-10a overexpression and MDM4 downregulation. Furthermore, we determined an inverse association between miR-10a and MDM4 expression in AML (IR) samples with respect to their NPM1 mutational status.
CONCLUSIONS: miR-10a expression is highly characteristic for AML (IR) patients with NPM1 mutations and may influence its biological properties in AML by interfering with the p53 machinery partly regulated by MDM4.
Copyright © 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21784052     DOI: 10.1016/j.exphem.2011.07.008

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  26 in total

1.  MicroRNAs and tRNA-derived fragments predict the transformation of myelodysplastic syndromes to acute myeloid leukemia.

Authors:  Yan Guo; Stephen A Strickland; Sanjay Mohan; Shaoying Li; Amma Bosompem; Kasey C Vickers; Shilin Zhao; Quanhu Sheng; Annette S Kim
Journal:  Leuk Lymphoma       Date:  2017-01-13

Review 2.  microRNAs and Alu elements in the p53-Mdm2-Mdm4 regulatory network.

Authors:  Yonit Hoffman; Yitzhak Pilpel; Moshe Oren
Journal:  J Mol Cell Biol       Date:  2014-06       Impact factor: 6.216

3.  Induction of multiple myeloma bone marrow stromal cell apoptosis by inhibiting extracellular vesicle miR-10a secretion.

Authors:  Tomohiro Umezu; Satoshi Imanishi; Seiichiro Yoshizawa; Chiaki Kawana; Junko H Ohyashiki; Kazuma Ohyashiki
Journal:  Blood Adv       Date:  2019-11-12

Review 4.  The effects of microRNAs on glucocorticoid responsiveness.

Authors:  Huimin Wang; Xuxu Gou; Tang Jiang; Juan Ouyang
Journal:  J Cancer Res Clin Oncol       Date:  2017-03-12       Impact factor: 4.553

5.  Understanding the role of miRNA in regulating NF-κB in blood cancer.

Authors:  Stuart A Rushworth; Megan Y Murray; Lawrence N Barrera; Sally-Anne Heasman; Lyubov Zaitseva; David J Macewan
Journal:  Am J Cancer Res       Date:  2011-11-21       Impact factor: 6.166

6.  Serum level of miR-10-5p as a prognostic biomarker for acute myeloid leukemia.

Authors:  Yongjin Zhi; Xiaobao Xie; Rong Wang; Biao Wang; Weiying Gu; Yun Ling; Weimin Dong; Feng Zhi; Yan Liu
Journal:  Int J Hematol       Date:  2015-07-02       Impact factor: 2.490

Review 7.  Dysfunctional diversity of p53 proteins in adult acute myeloid leukemia: projections on diagnostic workup and therapy.

Authors:  Miron Prokocimer; Alina Molchadsky; Varda Rotter
Journal:  Blood       Date:  2017-06-12       Impact factor: 22.113

Review 8.  MDM4 alternative splicing and implication in MDM4 targeted cancer therapies.

Authors:  Jin Wu; Guanting Lu; Xinjiang Wang
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

9.  Overexpression of miR-10a and miR-375 and downregulation of YAP1 in medullary thyroid carcinoma.

Authors:  Jena Hudson; Eric Duncavage; Anna Tamburrino; Paolo Salerno; Liqiang Xi; Mark Raffeld; Jeffrey Moley; Rebecca D Chernock
Journal:  Exp Mol Pathol       Date:  2013-05-16       Impact factor: 3.362

10.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.